Skip to main content

Replimune Group, Inc.

REPL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001737953

In the last 90 days, Replimune Group, Inc. insiders filed 0 open-market purchases and 5 sales; 199 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Replimune Group, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of REPL: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders141127−14
Shares54.6M56.8M+2.21M (+4.0%)
Value$1.27B$970.9M−$296.4M (−23.4%)

New holders (9)

Institutions that held Replimune Group, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to REPL in Q3 2023
InstitutionSharesValue% of portfolio
Great Point Partners LLC638,495$10.9M2.06%
Verition Fund Management LLC299,217$5.12M0.07%
Sphera Funds Management Ltd.185,016$3.17M0.76%
Acuta Capital Partners, LLC150,000$2.57M1.87%
Occudo Quantitative Strategies LP58,017$992.7K0.13%
Lion Point Capital, LP35,000$598.9K0.55%
Graham Capital Management, L.P.19,867$339.9K0.01%
XTX Topco Ltd12,387$211.9K0.04%
First Trust Advisors LP10,020$171.4K0.00%

Sold out (23)

Institutions that held Replimune Group, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.